ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy

Liu, Xiguang; Zheng, Yating; Mai, Shijie; Tong, Yu; Yang, Lili; Huang, Mengli; Cai, Ruijun*南方医科大学
Frontiers in Oncology2022-11-25DOI: 10.3389/fonc.2022.1033322
12阅读
引用收藏
分享

摘要

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) provide dramatic response to patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, the use of neoadjuvant therapy with EGFR-TKIs in EGFR-mutant NSCLC remains controversial, especially in pulmonary sarcomatoid carcinoma (PSC). One patient with initially unresectable stage III (cT4N0M0) PSC was found to carry EGFR mutation by the next generation sequencing. After neoadjuvant therapy with osimertinib plus chemotherapy, radical resection of the right upper lung lesion was achieved, and the pathological results reached pathological complete response (pCR). To the best of our knowledge, this is the first report of an EGFR-mutant patient with initially unresectable stage III PSC achieved pCR by neoadjuvant therapy with osimertinib plus chemotherapy. Therefore, neoadjuvant therapy with EGFR-TKIs may be a viable option for EGFR-mutant PSC patients.

学科与关键词

关键词
pulmonary sarcomatoid carcinomaosimertinibchemotherapyneoadjuvantEGFR
相关
加载中…
  • Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
    Lv, Chao; Fang, Wentao; Wu, Nan; Jiao, Wenjie; Xu, Shidong; Ma, Haitao; Wang, Jia; Wang, Rui; Ji, Chunyu; Li, Shaolei; Wang, Yuzhao; Yan, Shi; Lu, Fangliang; Pei, Yuquan; Liu, Yinan; Yang, Yue*Lung Cancer, 2023, 178: 151-156.被引 10
  • Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
    Lyu, C.; Fang, W.; Jiao, W.; Ma, H.; Wang, J.; Xu, S.; Wu, N.; Wang, R.; Yang, Y.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 7
  • Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
    Shi, Xiaoshun; Dong, Xiaoying; Zhai, Jianxue; Liu, Xiguang; Lu, Di; Ni, Zhen; Wu, Hua; Cai, Kaican*Frontiers in Oncology, 2021, 11: 608608.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-11-25
卷期
第 12 卷
页码
1033322
DOI
10.3389/fonc.2022.1033322
期刊等级
3区
成果收录
SCIE

作者

  • L

    Liu, Xiguang (第一作者)

    southern med univ

  • Z

    Zheng, Yating

查看全部 7 位作者收起作者
  • M

    Mai, Shijie

    southern med univ

  • T

    Tong, Yu

    southern med univ

  • Y

    Yang, Lili

    southern med univ

  • H

    Huang, Mengli

  • C

    Cai, Ruijun (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417